IP Library Granted Patent US 7,838,516
Granted Patent B2
US 7,838,516 · App. 11/662,166 · Granted Nov 23, 2010

15 β-substituted steroids having selective estrogenic activity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,838,516
App. No.
11/662,166
Granted
Nov 23, 2010
Kind
B2
Abstract

The invention provides 15β-substituted steroidal compounds having selective estrogen receptor activity according to Formula I: wherein, R 1 is H, C 1-5 alkyl, C 1-12 acyl, di-(C 1-5 alkyl)aminocarbonyl, (C 1-5 alkyl)oxycarbonyl or sulfamoyl, R 2 is H, C 1-3 alkyl, C 2-3 alkenyl or C 2-3 alkynyl, each of which may be optionally substituted with a halogen, R 3 is C 1-2 alkyl, ethenyl or ethynyl, each of which may be optionally substituted with a halogen, and R 4 is H or C 1-12 acyl.

Claims (17)

1. A 15β-substituted steroidal compound of Formula I:

wherein R 1 is H, C 1-5 alkyl, C 1-12 acyl, di-(C 1-5 alkyl)aminocarbonyl, (C 1-5 alkyl)oxycarbonyl or sulfamoyl;

R 2 is C 1-3 alkyl, C 2-3 alkenyl or C 2-3 alkynyl, each of which may be optionally substituted with a halogen;

R 3 is C 1-2 alkyl, ethenyl or ethynyl, each of which may be optionally substituted with a halogen; and

R 4 is H or C 1-12 acyl.

2. The compound according to claim 1 , wherein R 1 and R 4 are both H.

3. The compound according to claim 1 , wherein the compound is 7α-ethyl-15β-methyl-19-nor-17α-pregna- 1,3,5(10)-trien-20-yne-3,17β-diol.

4. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

5. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutical acceptable excipient.

7. A method for the treatment of a disease or condition selected from the group consisting of osteoporosis and climacteric complaints, wherein the climacteric complaints are selected from the group consisting of hot flushes, sweating and mood swings, the method comprising: administering to a human an effective amount of the compound according to claim 1 .

8. The method according to claim 7 , wherein the disease or condition is climacteric complaints.

9. The method according to claim 7 , wherein the disease or condition is osteoporosis.

10. A method of contraception comprising: administering to a woman an effective amount of the compound according to claim 1 .

11. A method of treating osteoporosis in a human comprising: administering to the human an effective amount of the compound according to claim 3 .

12. A method of treating climacteric complaints selected from the group consisting of hot flushes, sweating and mood swings in a human comprising: administering to the human an effective amount of the compound according to claim 3 .

13. A method of contraception comprising: administering to a woman an effective amount of the compound according to claim 3 .

Assignments (4)
MERGER Recorded Mar 8, 2013
From: ORGANON BIOSCIENCES NEDERLAND B.V.
To: MERCK SHARP & DOHME B.V.
Reel/Frame 029940/0296 →
MERGER Recorded Mar 7, 2013
From: MSD OSS B.V.
To: ORGANON BIOSCIENCES NEDERLAND B.V.
Reel/Frame 029939/0001 →
MERGER Recorded Dec 1, 2011
From: N.V. ORGANON
To: MSD OSS B.V.
Reel/Frame 027307/0482 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2007
From: LOOZEN, HUBERT JAN JOZEF; EDERVEEN, ANTONIUS GERARDUS HENDRIKUS; DIJCKS, FREDERICUS ANTONIUS
To: N.V. ORGANON
Reel/Frame 019058/0221 →